APFID

Home > Latest News on ID > Interesting Papers

LOGIN
New insights on pneumococcal disease: what we have learned over the past decade
Vaccine. 2009;27 Suppl 3:C3-5
Date: 2009-08-26   Read: 156447

Vaccine. 2009 Aug 21;27 Suppl 3:C3-5

New insights on pneumococcal disease: what we have learned over the past decade

Dagan R.

Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2000, significant reductions in the rate of invasive pneumococcal diseases (IPDs) and mucosal infections caused by vaccine-specific serotypes have been observed in the targeted population (children aged <5 years). IPD rates have also decreased in adults aged >/=65 years, suggesting the extension of vaccine protection to the unimmunized population. A concomitant decline has been noted in antibiotic-resistant Streptococcus pneumoniae isolates. The incidence of vaccine-serotype IPD varies widely in geographically disparate regions, indicating that serotype coverage alone may not accurately predict the impact of proposed pneumococcal conjugate vaccines with additional serotypes.



Next Understanding the link between pneumococcal serotypes and invasive disease
Vaccine. 2009;27 Suppl 3:C19-21
2009-08-26 156901
Previous Why is community-associated MRSA spreading across the world and how will it change clinical practice?
Int J Antimicrob Agents. 2009;34 Suppl 1:S15-9.
2009-07-27 157424
޴ٷΰ ΰ